Parkinson’s disease (PD), the second most common neurodegenerative disorder globally, relies primarily on dopamine replacement therapy for conventional treatment. This approach fails to reverse core pathological processes and is associated with long-term side effects. Recent research on the microbiota-gut-brain axis (MGBA) has revealed that PD pathology may originate in the gut, forming a vicious cycle from the gut to brain through α-synuclein propagation, gut dysbiosis, intestinal barrier disruption, and neuroinflammation. This offers a novel perspective for managing PD through dietary interventions that modulate the gut microbiome. However, single probiotic or prebiotic interventions show limited efficacy. This review systematically introduces the novel concept of “synbiotics combining medicinal plant polysaccharides with probiotics,” aiming to integrate traditional “medicinal food” wisdom with modern microbiome science. The article systematically elucidates the pathological mechanisms of MGBA dysfunction in PD and the intervention mechanisms of probiotics and emphasizes the structural and functional advantages of medicinal plant polysaccharide as superior prebiotics. The core section delves into the multifaceted synergistic mechanisms between these two components: enhancing probiotic colonization and vitality, optimizing microbial metabolic output, synergistically reinforcing the intestinal and blood-brain barriers, and jointly regulating immune and neuroinflammation. This approach targets the MGBA to achieve multi-level intervention for PD.
Diabetes is a global disease that can lead to a range of complications. Currently, the treatment of type 2 diabetes focuses on oral hypoglycemic drugs and insulin analogues. Studies have shown that drugs such as oral metformin are useful in the treatment of diabetes but can limit the liver’s ability to release sugar. The development of glucose-lowering peptides has provided new options for the treatment of type 2 diabetes. Peptide drugs have low oral utilization due to their easy degradation, short half-life, and difficulty passing through the intestinal mucosa. Therefore, improving the oral utilization of peptide drugs remains an urgent problem. This paper reviews the research progress of peptide drugs in the treatment of diabetes mellitus and proposes that different types of nano-formulation carriers, such as liposomes, self-emulsifying drug delivery systems, and polymer particles, should be combined with peptide drugs for oral administration to improve their absorption in the gastrointestinal tract.
Most patients with irritable bowel syndrome have diarrhea or constipation, two opposite bowel habits. Although defecation habits represent opposing phenotypes, patients across all subtypes exhibit visceral hypersensitivity. This review explores the common pathway that causes visceral hypersensitivity: the mast cell–PAR2–TRP axis. The mechanism involves tryptase released by mast cells. Furthermore, tryptase activates PAR2, which sensitizes downstream TRP ion channels that conduct pain signals. The review also examines the factors leading to the formation of different fecal characteristics. In terms of treatment, this review also summarizes therapeutic agents targeting different components of this axis. Future pharmaceutical research should focus more on the mast cell–PAR2–TRP axis.
Remodeling of adipose tissue macrophages (ATMs) during obesity is closely linked to insulin resistance. In addition to soluble mediators, extracellular vesicles (EVs) released by ATMs and their microRNA (miRNA) cargo have been implicated in metabolic communication between adipose tissue and skeletal muscle. Previous studies have shown that EV cargo profiles and metabolic effects can vary across ATM states, adipose depots, and macrophage populations, with some EVs promoting insulin resistance and others improving insulin sensitivity. Among the mechanisms relevant to skeletal muscle, the miR-29a–PPARδ relationship has relatively direct experimental support from ATM-EV studies. The miR-210-3p–GLUT4 relationship is supported by changes in ATM-EV cargo, findings from myocytes and other recipient-cell models, and experiments involving exogenously administered macrophage EVs. However, this relationship has not been fully validated within a single ATM-EV–skeletal muscle experimental system. Studies involving miR-690 also suggest that EVs from certain macrophage populations can improve insulin sensitivity, although the molecular annotation of miR-690, its reported direct targeting mechanism, and the applicability of these findings to humans remain under debate. Overall, these findings implicate ATM-derived EVs in metabolic regulation, while their physiological effects on skeletal muscle in humans remain uncertain.
Dysmenorrhea is common among women of reproductive age and may be primary, without identifiable pelvic pathology, or secondary to conditions such as endometriosis, adenomyosis, uterine fibroids, and pelvic inflammatory disease. Reproductive endocrine disorders, including polyendocrine metabolic ovarian syndrome [PMOS; formerly polycystic ovary syndrome (PCOS)], may coexist with menstrual pain and influence reproductive assessment and treatment decisions, particularly when irregular cycles or ovulatory dysfunction are present. However, treatment should address current symptom burden and its effects on daily functioning and quality of life while also considering reproductive timing and fertility-related risks when relevant. Some hormonal therapies used for symptom control are incompatible with attempts at natural conception, while continued symptomatic treatment without reassessment may delay recognition of secondary causes that can affect fertility. This narrative review integrates evidence on symptom control, the fertility implications of secondary causes of dysmenorrhea and coexisting reproductive endocrine disorders, clinical features that warrant earlier etiologic assessment, pain management during the preconception period, and the influence of diagnostic findings and etiologic treatment on reproductive decisions. We propose a clinically oriented framework in which the timing of symptom control, further evaluation, and treatment is adjusted according to symptom characteristics, treatment response, clinical concern for secondary causes, and reproductive goals. Such an approach may help balance effective pain relief with timely etiologic assessment and individualized fertility planning.